The Spain pharmaceutical market is on a steady upward path, supported by an ageing population, deeper R&D spending and a growing appetite for biologics and biosimilars. The industry reached USD 27.84 Billion in 2025 and is projected to reach USD 42.92 Billion by 2034, growing at a compound annual growth rate (CAGR) of 4.92% during 2026-2034. Spain’s drug makers invest more than €1.5 billion in R&D every year and secured nearly 930 clinical trial approvals in 2024, the highest in Europe, while exports of roughly €17 billion account for about 80% of what the sector produces. That combination of a strong domestic payer, an export-minded manufacturing base and a deep clinical research network gives the market a stability that few European peers can match. It matters well beyond healthcare too, since it feeds high-skilled employment, regional biotech clusters and the country’s external trade balance.
The Spain pharmaceutical market is set for measured, policy-backed expansion. With a projected CAGR of 4.92% through 2034, a record research pipeline and a reform agenda aimed at faster access to innovative medicines, it offers room for established manufacturers and for newer players focused on biosimilars, precision medicine and digital dispensing.
SPAIN PHARMACEUTICAL MARKET SUMMARY
- Scope: The Spain pharmaceutical market covers drug discovery, active pharmaceutical ingredient (API) production, formulation, regulatory approval and distribution through retail, hospital and ambulatory dispensing channels.
- Ecosystem: Domestic manufacturers, multinational subsidiaries, contract development organizations, biotech firms, wholesalers and community and hospital pharmacies all take part, with the Spanish Agency of Medicines and Medical Devices (AEMPS) and the European Medicines Agency (EMA) overseeing approvals.
- Key segments: The report divides the market by type (pharmaceutical drugs and biologics), nature (conventional and organic) and region (Central, Eastern, Northern and Southern Spain).
- Segment leaders: Pharmaceutical drugs hold 72.8% of the market, conventional products account for 91.7%, and Central Spain leads regionally with a 35.8% share (2025).
- Market trajectory: Value rose from USD 21.89 Billion in 2020 to USD 27.84 Billion in 2025, and is expected to reach USD 35.41 Billion in 2030 before touching USD 42.92 Billion in 2034.
- Fastest-growing pockets: Biologics (estimated ~6.8% CAGR) and organic products (estimated ~7.2% CAGR) are expanding quicker than the overall market, though from smaller bases.
PORTER’S FIVE FORCES ANALYSIS – SPAIN PHARMACEUTICAL MARKET
The competitive dynamics of the Spain pharmaceutical market can be read through Porter’s Five Forces framework.
Porter’s Five Forces Analysis – Spain Pharmaceutical Market
- Competitive Rivalry: Moderate to High. Multinational innovators and home-grown companies such as Grifols, Almirall, ROVI, Kern Pharma and FAES Farma compete across branded, generic and biosimilar lines, and patent expiries keep pushing generic competition up. Business implication: companies need a clear edge in a specialty area, whether plasma-derived products, dermatology or injectables, and a steady pipeline to protect share as exclusivity ends.
- Supplier Power: Moderate. Spanish producers depend heavily on imported APIs, much of it from Asia, and on specialised equipment for biologics manufacturing. Disruptions and currency swings can squeeze margins, although European autonomy initiatives and the new “strategic medicine” concept are widening local supply options. Business implication: dual sourcing, European API partnerships and capacity investment reduce exposure.
- Buyer Power: High. The National Health System and regional health authorities buy most of the volume and shape prices through reference pricing, price-volume agreements and centralised procurement. Order SND/1053/2026 added 26 new reference groups this year. Business implication: manufacturers must build strong health-economic evidence and negotiate access early, since reimbursement terms decide revenue.
- Threat of Substitutes: Moderate. Generics and biosimilars replace branded therapies as patents lapse, and digital care models and preventive programmes can lower drug use at the margin. Business implication: lifecycle management, differentiated formulations and value-based positioning help originators defend their products.
- Threat of New Entrants: Low to Moderate. Regulatory approval through AEMPS and the EMA, GMP compliance, capital needs and reimbursement hurdles keep the barriers high for new drug makers, while niche biotechs, contract developers and digital pharmacy platforms find it easier to get in. Business implication: incumbents should keep investing in scale, regulatory know-how and partnerships with emerging biotechs.
Competitive Rivalry – Moderate to High (Healthy)
- Competition runs across several tiers: plasma and biologics leaders (Grifols), specialty innovators (Almirall), injectable and biosimilar specialists (ROVI) and cost-focused generic makers (Kern Pharma), with research partnerships and capacity investment, rather than pure price cutting, driving differentiation.
- Grifols’ €160 million plasma fractionation plant in Lliçà de Vall, which began construction in June 2026, and Almirall’s July 2026 mRNA research collaboration with Certest Biotec show active repositioning that is strengthening the wider ecosystem. Almirall also reported H1 2026 net sales growth of 7.5% to €602.7 million.
Request for Sample Report: https://www.imarcgroup.com/spain-pharmaceutical-market/requestsample
MARKET GROWTH DRIVERS:
Several factors are lifting the Spain pharmaceutical market. The ageing population and heavier chronic disease burden keep demand rising for cardiovascular, oncology, diabetes and neurodegenerative treatments, and manufacturers are responding with formulations built for older patients. At the same time, rising R&D investment is widening the pipeline: drug makers put more than €1.5 billion into Spanish research in 2024, and the country authorised close to 930 clinical trials that year, giving hospitals and biotech groups a steady flow of partnership work. Policy is also pulling in the same direction, with the 2024-2028 Pharmaceutical Industry Strategy aiming to boost research, strategic autonomy and the use of generics and biosimilars.
MARKET GROWTH DRIVERS:
Product and policy shifts add further momentum. The expansion of biopharmaceuticals and biosimilars is lowering treatment costs and widening access to monoclonal antibodies, therapeutic proteins and vaccines, while domestic manufacturers scale up bioreactor and purification capacity. Generic adoption keeps volumes growing as reference pricing and patent expiries encourage substitution, and the Medicines and Medical Devices Bill approved by the Council of Ministers on 21 July 2026 targets a 180-day limit for pricing and financing decisions, with estimated annual savings of €2.1 billion. Finally, digital health integration, including e-prescription and telepharmacy, is improving medicine access in rural and ambulatory settings and opening new direct-to-patient channels.
SPAIN PHARMACEUTICAL MARKET SEGMENTATION
Segmentation analysis provides a detailed view of the Spain pharmaceutical market by category:
- Type Insights: Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs) and Biologics (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines).
- Nature Insights: Conventional, Organic.
- Regional Insights: Central Spain, Eastern Spain, Northern Spain, Southern Spain.
COMPETITIVE LANDSCAPE
The Spain pharmaceutical market is moderately fragmented, with no single manufacturer holding a dominant share. Multinational subsidiaries lead in biologics, oncology and specialty innovation, while domestic companies defend their positions in generics, injectables and biosimilars. Key companies operating in the market include:
- Grifols, S.A.
- Almirall
- Laboratorios Farmacéuticos ROVI, S.A.
- Kern Pharma
- FAES Farma
Recent moves are reshaping the field. Grifols began building a €160 million plasma fractionation site in Lliçà de Vall (Barcelona) in June 2026, due to start operating in 2030 and add 3 million litres of annual capacity in Europe, and Almirall signed a research and licensing collaboration with Spanish biotech Certest Biotec in July 2026 to develop treatments for rare dermatologic diseases.
REGIONAL ANALYSIS:
Regional dynamics within the Spain pharmaceutical market reflect where manufacturers, research centres and hospital networks are concentrated.
- Central Spain (35.8% share in 2025): Madrid’s concentration of manufacturers, research institutes, hospital networks and regulatory functions makes it the largest regional market.
- Eastern Spain (27.4%): Catalonia’s biotech clusters, export-oriented production and strong ambulatory care infrastructure support the second-largest share.
- Northern Spain (19.3%): Established generics manufacturing hubs and rising investment in biosimilar production drive activity.
- Southern Spain (17.5%): Expanding healthcare infrastructure and growing chronic disease treatment demand are improving access and regional distribution.
RECENT INDUSTRY DEVELOPMENTS
October 2026: Spain’s Cortes Generales were dissolved on 6 October ahead of a general election on 29 November 2026, interrupting the parliamentary passage of the Medicines and Medical Devices Bill and other pending health measures.
October 2026: The Ministry of Health’s Order SND/1053/2026, published in the Official State Gazette (BOE) on 7 October, updated the reference pricing system, creating 26 new reference groups; the new retail prices apply from 1 December 2026.
July 2026: Almirall announced a strategic research collaboration and licensing agreement with Certest Biotec (Zaragoza) to discover and develop treatments for rare dermatologic diseases and recurrent cutaneous conditions, combining Certest’s mRNA and lipid nanoparticle platform with Almirall’s dermatology expertise.
July 2026: On 21 July, the Council of Ministers approved the Medicines and Medical Devices Bill, aiming to guarantee the 180-day pricing and financing deadline, introduce strategic medicines and dynamic pricing for off-patent products, and recognise nurse and physiotherapist prescribing.
June 2026: Grifols held the groundbreaking for a new plant in Lliçà de Vall, Barcelona, with an initial investment of €160 million, adding 3 million litres of annual plasma fractionation capacity in Europe and creating around 400 jobs; operations are expected to begin in 2030.
May 2026: Royal Decree-Law 11/2026 of 12 May reformed the patient co-payment system for outpatient medicines, tying contributions to income level and introducing new monthly caps.
Key Aspects Required for the Spain Pharmaceutical Market
- Market Performance: USD 27.84 Billion in 2025, with a projected trajectory to USD 42.92 Billion by 2034.
- Market Outlook: A 4.92% CAGR through 2034 indicates steady growth across pharmaceutical drugs and biologics, with the market anchored at USD 35.41 Billion in 2030.
- Growth Drivers: An ageing population and chronic disease burden; rising R&D and clinical trial activity; biosimilar and biologics expansion; generic adoption supported by cost-containment policy; digital health and e-prescription adoption.
- Competitive Landscape: A moderately fragmented structure with domestic leaders and generics specialists (Grifols, Almirall, ROVI, Kern Pharma, FAES Farma) alongside multinational subsidiaries, with consolidation increasing through partnerships and acquisitions.
- Value Chain Analysis: From R&D and drug discovery through API and bulk manufacturing, formulation and finished dosage, regulatory approval and quality control, and distribution, to retail, hospital and ambulatory dispensing.
- Industry Trends: AI-driven drug discovery; biosimilar and biologics manufacturing expansion; personalised and precision medicine adoption; digital health integration reshaping drug retail.
- Strategic Recommendations: Focus on biosimilar and injectable manufacturing capacity, oncology-focused API investment and digital pharmacy infrastructure; build early partnerships with regional health authorities and hospital networks; diversify API sourcing to reduce import dependency.
Note: If you need any specific information that is not covered currently within the scope of the report, we will provide the same as a part of customization.
Request Customization: https://www.imarcgroup.com/request?type=report&id=22999&flag=E
- Report Format, Delivery, and Customization Details
- Report Format Mode: PPT, PDF, and Excel
- Report Delivery Mode: Online Delivery, Physical Delivery
- Report Delivery Time: Report Delivered Over Email within 24 to 48 hours. If requested by the client, a physical copy will be delivered within three to ten days.
- Report Confirmation Mode: Yes via Email
- Report Customization Mode: Yes via Email / Call
- Report Table of Content: Yes
- Report List of Figures: Yes
- Report Methodology Mode: Yes
- Request For Sample Report: Yes
